Keywords
irinotecan
mitomycin C
How to Cite
Abstract
Information on 60 patients with gastric cancer T3N0-2M0 has been studied. 30 patients (the basic group) received complex treatment including gastrectomy, during operations and postoperative chemotherapy irinotecan with mitomycin . 30 patients (control group) after operations gastrectomy are spent courses of standard intravenous chemotherapy. Complex treatment of patients with resectable gastric cancer with application of chemotherapy irinotecan with mitomycin during gastrectomy and postoperative period promotes decrease in frequency of progressing of disease on 20 % for 18 months of supervision, authentically improves a current of the postoperative period, promotes decrease in frequency of occurrence of postoperative complications on 30%, interferes with hypercoagulation development, normalising coagulant blood system, leads to the expressed hypostasis stromas to a tumour and stimulation of fabric T-cellular immunityReferences
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer / A.M. Murad, F.F. Santiago, A. Petroianu et al. // Cancer. – 1993. – Vol. 72, № 1. – Р. 37–41.
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer / S. Pyrhonen, T. Kuitunen, P. Nyandoto, M. Kouri // British J. Cancer. – 1995. – Vol. 71, № 3. – Р. 587–591.
Phase ii study of a combination of irinotecan and cisplatin against metastatic gastric cancer / N. Boku, A. Ohtsu, Y. Shimada et al. // J. Clinical Oncology. – 1999. – Vol. 17, № 1. – Р. 319–323.
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial / W. Koizumi, H. Narahara, T. Hara et al. // Lancet Oncology. – 2008. – Vol. 9, № 3. – Р. 215–221.
Initial or delayed chemotherapy with best supportive care in advanced gastric cancer / B. Glimelius, K. Hoffman, U. Haglund, O. Nyren, P. O. Sjoden // Annals of Oncology. – Vol. 5, № 2. – Р. 189–190.
Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschft Internische Onkologie (AIO) / P.C. Thuss-Patience, A. Kretzschmar, T. Deist / J. Clinical Oncology. – Vol. 27, abstract 4540.
Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer / K. Futatsuki, A. Wakui, I. Nakao et al. / Japanese J. Cancer and Chemotherapy. – 1994. – Vol. 21, № 7. – Р. 1033–1038.
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study / N. Boku, S. Yamamoto, H. Fukuda et al. // Lancet Oncology. – 2009. – Vol. 10, № 11. – Р. 1063–1069.
Актуальные вопросы химиотерапии рака желудка / Г.В. Бондарь, А.В. Сидюк, Н.Ю. Лисовская и др. // Международный медицинский журнал. – 2012. – № 1. – С. 79–83.
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer / T. Yamao, K. Shirao, Y. Matsumura et al. // Annals of Oncology. – 2001. – Vol. 12, № 12. – Р. 1729–1735.
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial / J.A. Ajani, W. Rodriguez, G. Bodoky et al. / J. Clinical Oncology. – 2010. – Vol. 28, № 9. – Р. 1547–1553.
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer / A. Bamias, D. Papamichael, K. Syrigos, N. Pavlidis / J. Chemotherapy. – 2003. – Vol. 15, № 3. – Р. 275–281.
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia meridionale (prot 2106) / F. Giuliani, S. Molica, E. Maiello et al. // Am. J. Clinical Oncology. – 2005. – Vol. 28, № 6. – Р. 581–585.
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen / • S.H. Kim, G.W. Lee, S.I. Go et al. // Am. J. Clinical Oncology. – 2010. – Vol. 33, № 6. – Р. 572–576.